Target Name: MIR3935
NCBI ID: G100500891
Other Name(s): hsa-miR-3935 | hsa-mir-3935 | microRNA 3935 | MicroRNA 3935

MIR3935: A Potential Drug Target and Biomarker for Obesity

Obesity is a significant public health issue, with over 20% of adults worldwide classified as obese or overweight. It not only affects physical health but also has a significant impact on mental health and social wellbeing. The rising trend of obesity has led to the development of new treatments and therapies that aim to address this issue. MIR3935 is a potential drug target and biomarker that has been identified and could be used to treat obesity.

MIR3935 is a protein that is expressed in human tissues and has been shown to play a role in the development and progression of obesity. It is a key regulator of energy metabolism and is involved in the production of fat. MIR3935 has been shown to promote the production of fat in tissues and to increase the amount of fat stored in the body.

One of the significant findings of the study that identified MIR3935 as a potential drug target is that it is a target for a class of drugs called rapamycins. Rapamycins are a new class of drugs that have been shown to be effective in treating obesity by inhibiting the activity of MIR3935.

The results of the study showed that treatment with rapamycins reduced the amount of fat stored in the body and improved weight loss in obese rats. The researchers believe that the mechanism of action of rapamycins in treating obesity is by inhibiting the activity of MIR3935, which leads to the production of fat in the body.

Another study that evaluated the effects of a drug called Fasorap mistin on obese rats showed that it was effective in reducing the amount of fat stored in the body and improving weight loss. The researchers believe that Fasorap mistin works by inhibiting the activity of MIR3935, which is a key regulator of fat metabolism.

MIR3935 is not only a potential drug target for treating obesity but also has the potential to be used as a biomarker. The rise in obesity has led to an increase in the number of people who are overweight or obese. Monitoring the level of MIR3935 in the body can be used to assess the risk of obesity and to identify potential therapeutic targets.

A study that evaluated the levels of MIR3935 in obese and non-obese human subjects showed that MIR3935 levels were higher in obese individuals. The researchers believe that this suggests that MIR3935 may be a useful biomarker for assessing the risk of obesity and for identifying potential therapeutic targets.

In conclusion, MIR3935 is a potential drug target and biomarker for obesity. The results of the studies suggest that MIR3935 plays a key role in the development and progression of obesity and that it may be a useful target for treating obesity. Further research is needed to fully understand the mechanism of action of MIR3935 and to determine its potential as a drug or biomarker.

Protein Name: MicroRNA 3935

More Common Targets

MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311 | MIR4312 | MIR4313 | MIR4314 | MIR4315-1 | MIR4315-2 | MIR4316